Delve Bio has launched a plasma metagenomic sequencing service designed to identify DNA and RNA pathogens using a database covering more than 68,000 organisms. The test promises results the day after sample receipt, but plasma-specific diagnostic accuracy and clinical utility remain important questions.
Find out how Cepheid’s Xpert Hemorrhagic Fever panel could reshape Ebola Bundibugyo testing in Africa amid urgent diagnostic gaps.
Zepto’s FungiFlex brings liquid biopsy to invasive mold infections. The FDA designation tests whether faster fungal diagnosis can change care.
Saudi localization gives Co-Diagnostics a new opening. The test is whether CoMira can turn a factory lease into diagnostics traction.
Molecular testing is powerful but lab-bound. Seek Labs’ patent raises a sharper question: can point-of-care diagnostics finally scale?
Invivoscribe’s IdentiClone Dx IGH won IVDR certification in the EU. Read what this means for clonality testing, lab adoption, and diagnostic competition.
QIAGEN wins FDA clearance for GI panels on QIAstat-Dx Rise. Discover what this means for syndromic testing platforms and molecular diagnostics adoption.
Insight Molecular Diagnostics advances GraftAssureDx toward FDA submission. Discover what this means for transplant rejection testing and dd-cfDNA diagnostics.
Belay Diagnostics validates its Summit 2.0 CSF genomic assay, strengthening the clinical case for liquid biopsy in CNS cancers. Read the full analysis.
NCCN guidelines now recommend Merlin CP-GEP for early-stage melanoma risk assessment. Discover what this changes for clinicians and diagnostics adoption.